MCID: ART008
MIFTS: 42

Arteriosclerosis Obliterans

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

MalaCards integrated aliases for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 37 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
MeSH 44 D001162
SNOMED-CT 68 361133006 60625000
KEGG 37 H01626
UMLS 73 C0003851

Summaries for Arteriosclerosis Obliterans

MalaCards based summary : Arteriosclerosis Obliterans is related to peripheral artery disease and peripheral vascular disease. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are HTLV-I infection and Cell adhesion molecules (CAMs). The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and bone marrow, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 76 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 30.3 IL6 SELP VCAM1
2 peripheral vascular disease 30.1 IL6 SELP VCAM1
3 chronic venous insufficiency 30.0 ICAM1 SELP VCAM1
4 venous insufficiency 30.0 ICAM1 SELP VCAM1
5 arteriosclerosis 29.7 ADIPOQ HGF ICAM1 IL6 SELP VCAM1
6 myocardial infarction 29.6 ADIPOQ ICAM1 IL6 SELP
7 intermittent claudication 29.5 HTR2A IL6 SELP
8 arteries, anomalies of 29.2 ADIPOQ ICAM1 IL6 SELP VCAM1
9 vascular disease 28.9 ADIPOQ ICAM1 IL6 SELP VCAM1
10 coronary artery anomaly 28.9 ADIPOQ ICAM1 IL6 SELP VCAM1
11 obesity-hypoventilation syndrome 10.7 ADIPOQ IL6
12 intermediate coronary syndrome 10.6 IL6 SELP
13 prediabetes syndrome 10.5 ADIPOQ IL6
14 chronic eosinophilic pneumonia 10.5 ICAM1 IL6
15 lymphocytic vasculitis 10.5 ICAM1 VCAM1
16 cortical thymoma 10.5 ICAM1 VCAM1
17 mooren's ulcer 10.5 ICAM1 VCAM1
18 subendocardial myocardial infarction 10.5 ICAM1 VCAM1
19 hypersensitivity reaction type iii disease 10.5 ICAM1 IL6
20 actinic prurigo 10.5 ICAM1 VCAM1
21 post-thrombotic syndrome 10.5 ICAM1 IL6
22 rheumatoid vasculitis 10.5 ICAM1 VCAM1
23 macular retinal edema 10.5 ICAM1 IL6
24 limbal stem cell deficiency 10.5 ICAM1 VCAM1
25 coronary artery aneurysm 10.4 ADIPOQ VCAM1
26 henoch-schoenlein purpura 10.4 ICAM1 VCAM1
27 leukostasis 10.4 ICAM1 VCAM1
28 shwartzman phenomenon 10.4 ICAM1 VCAM1
29 critical limb ischemia 10.4 HGF IL6
30 plasmodium vivax malaria 10.4 ICAM1 IL6
31 nodular goiter 10.4 ICAM1 IL6
32 diabetic macular edema 10.4 ICAM1 IL6
33 viral encephalitis 10.4 IL6 VCAM1
34 rheumatic heart disease 10.3 IL6 VCAM1
35 crescentic glomerulonephritis 10.3 ICAM1 VCAM1
36 dengue disease 10.3 ICAM1 VCAM1
37 diabetes mellitus 10.3
38 oral lichen planus 10.2 ICAM1 VCAM1
39 buerger disease 10.2
40 aneurysm 10.2
41 immune-complex glomerulonephritis 10.2 ICAM1 SELP VCAM1
42 primary progressive multiple sclerosis 10.2 ICAM1 VCAM1
43 heart disease 10.2
44 common cold 10.2 ICAM1 SELP
45 cytomegalovirus infection 10.1 ICAM1 IL6 VCAM1
46 ischemia 10.1
47 aortic aneurysm 10.1
48 synovitis 10.1 ICAM1 IL6 VCAM1
49 trypanosomiasis 10.1 ICAM1 IL6 VCAM1
50 ischemic heart disease 10.1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 ADIPOQ HGF ICAM1 IL6 MCAM SELP
2 hematopoietic system MP:0005397 9.17 ADIPOQ HGF ICAM1 IL6 MCAM SELP

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Probucol Approved, Investigational Phase 4 23288-49-5 4912
8
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
9 Analgesics Phase 4
10 Fibrinolytic Agents Phase 4
11 Respiratory System Agents Phase 4
12 Neuroprotective Agents Phase 4
13 Cyclooxygenase Inhibitors Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Vasodilator Agents Phase 4,Phase 2
16 Anti-Asthmatic Agents Phase 4
17 Peripheral Nervous System Agents Phase 4
18 Phosphodiesterase 3 Inhibitors Phase 4
19 Phosphodiesterase Inhibitors Phase 4
20 Platelet Aggregation Inhibitors Phase 4,Phase 2
21 Protective Agents Phase 4
22 Anti-Inflammatory Agents Phase 4
23 Antipyretics Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Antirheumatic Agents Phase 4,Not Applicable
26 Autonomic Agents Phase 4
27 Bronchodilator Agents Phase 4
28 diuretics Phase 4
29 Central Nervous System Depressants Phase 4
30 Narcotics Phase 4
31 Natriuretic Agents Phase 4
32 Sodium Chloride Symporter Inhibitors Phase 4
33 Analgesics, Opioid Phase 4
34 Anesthetics Phase 4,Phase 1,Phase 2
35 Anesthetics, General Phase 4
36 Anesthetics, Inhalation Phase 4
37 Anesthetics, Intravenous Phase 4
38 Angiotensin II Type 1 Receptor Blockers Phase 4
39 Angiotensin Receptor Antagonists Phase 4
40 Angiotensin-Converting Enzyme Inhibitors Phase 4
41 Angiotensinogen Phase 4
42 Hypnotics and Sedatives Phase 4
43 Hypolipidemic Agents Phase 4
44 Antihypertensive Agents Phase 4
45 Anticholesteremic Agents Phase 4
46 Antioxidants Phase 4
47 Lipid Regulating Agents Phase 4
48 Antimetabolites Phase 4
49
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
50 Anticoagulants Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4 cilostazol
2 Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
3 Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
4 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
5 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
6 Autologous Bone Marrow For Lower Extremity Ischemia Treating Completed NCT00753025 Phase 2
7 A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans Recruiting NCT02877173 Phase 2 Alprostadil Liposomes for Injection;Alprostadil Injection
8 Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Recruiting NCT02501018 Phase 2 SOC
9 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Enrolling by invitation NCT02864654 Phase 1, Phase 2
10 TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Unknown status NCT00145262
11 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
12 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F) Completed NCT01518205 Not Applicable
13 Arterial Calcification in the Diabetes Active, not recruiting NCT02431234
14 A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan Active, not recruiting NCT01859897
15 Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy Active, not recruiting NCT01984749 Not Applicable Febuxostat

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

41
Heart, Bone, Bone Marrow, Smooth Muscle, Skin, T Cells, Endothelial

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 249)
# Title Authors Year
1
MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie. ( 29403548 )
2018
2
Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients. ( 29553861 )
2018
3
The Association between Polymorphism of CARD8 rs2043211 and Susceptibility to Arteriosclerosis Obliterans in Chinese Han Male Population. ( 28135700 )
2017
4
Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans. ( 28848136 )
2017
5
Baseline Characterization of Japanese Peripheral Arterial Disease Patientsa88- Analysis of Surveillance of Cardiovascular Events in Antiplatelet-Treated Arteriosclerosis Obliterans Patients in Japan (SEASON). ( 26841805 )
2016
6
A Rare Complication of Spinal Cord Ischemia Following Endovascular Aneurysm Repair of an Infrarenal Abdominal Aortic Aneurysm with Arteriosclerosis Obliterans: Report of a Case. ( 27738476 )
2016
7
Emerging Novel Biomarkers for Arteriosclerosis Obliterans. ( 26632166 )
2016
8
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. ( 25959199 )
2015
9
MicroRNA-133a in the Development of Arteriosclerosis Obliterans. ( 25740337 )
2015
10
Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. ( 26370316 )
2015
11
Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. ( 26159387 )
2015
12
Logistic Regression Analysis of Depression in Arteriosclerosis Obliterans Patients and Its Risk Factors. ( 26564507 )
2015
13
MiR-142-3p attenuates the migration of CD4a8_ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. ( 24743945 )
2014
14
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. ( 25445891 )
2014
15
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( 23364237 )
2013
16
Relationship between Arteriosclerosis Obliterans and the Ratio of Serum Eicosapentaenoic Acid to Arachidonic Acid. ( 23364231 )
2013
17
Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. ( 23749750 )
2013
18
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. ( 22259111 )
2012
19
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. ( 23065872 )
2012
20
A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. ( 23097651 )
2012
21
MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. ( 21817107 )
2011
22
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. ( 20357749 )
2010
23
Characteristics of revascularization treatment for arteriosclerosis obliterans in patients with and without hemodialysis. ( 20938099 )
2010
24
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). ( 20966606 )
2010
25
Current status of the medical expenses for the treatment of arteriosclerosis obliterans in Japan. ( 20357751 )
2010
26
[Evaluation of proinflammatory cytokines in chronic lower limb ischaemia diabetic macroangiopathy and arteriosclerosis obliterans]. ( 20120706 )
2009
27
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. ( 19225945 )
2009
28
Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). ( 18724029 )
2008
29
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. ( 18375400 )
2008
30
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. ( 18270875 )
2008
31
Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans. ( 18175063 )
2008
32
Detecting vulnerable plaque of arteriosclerosis obliterans by multidetector-row computed tomography--comparing with VH (virtual histology)-intravascular ultrasound. ( 17512620 )
2008
33
Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. ( 17186986 )
2007
34
Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. ( 17652880 )
2007
35
Intractable wounds caused by arteriosclerosis obliterans with end-stage renal disease treated by aggressive debridement and epidermal grafting. ( 17637445 )
2007
36
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. ( 17126824 )
2007
37
Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. ( 18064333 )
2007
38
Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. ( 17610290 )
2007
39
[Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans]. ( 17087295 )
2006
40
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. ( 16763534 )
2006
41
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. ( 17249520 )
2006
42
Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. ( 16865304 )
2006
43
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. ( 15877296 )
2005
44
Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. ( 15080020 )
2004
45
The effect of Liple on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. ( 15765038 )
2004
46
Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. ( 14983238 )
2004
47
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. ( 15203718 )
2004
48
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. ( 15372302 )
2004
49
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. ( 15224807 )
2004
50
Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. ( 15564705 )
2004

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 MCAM SELP VCAM1
2 extracellular space GO:0005615 9.17 ADIPOQ HGF ICAM1 IL6 MCAM SELP

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.84 ICAM1 MCAM SELP VCAM1
2 response to lipopolysaccharide GO:0032496 9.69 ICAM1 SELP VCAM1
3 response to hypoxia GO:0001666 9.67 ADIPOQ ICAM1 VCAM1
4 cytokine-mediated signaling pathway GO:0019221 9.62 HGF ICAM1 IL6 VCAM1
5 negative regulation of fat cell differentiation GO:0045599 9.58 ADIPOQ IL6
6 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.57 ADIPOQ CARD8
7 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.56 HGF ICAM1
8 positive regulation of vasoconstriction GO:0045907 9.55 HTR2A ICAM1
9 response to ethanol GO:0045471 9.54 ADIPOQ ICAM1 VCAM1
10 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.52 ADIPOQ TPM1
11 negative regulation of tumor necrosis factor-mediated signaling pathway GO:0010804 9.48 ADIPOQ CARD8
12 calcium-mediated signaling using intracellular calcium source GO:0035584 9.46 SELP VCAM1
13 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.43 ADIPOQ TPM1
14 leukocyte tethering or rolling GO:0050901 9.4 SELP VCAM1
15 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.33 ICAM1 SELP VCAM1
16 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
17 leukocyte cell-cell adhesion GO:0007159 9.13 ICAM1 SELP VCAM1
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.02 ADIPOQ HGF HTR2A ICAM1 IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sialic acid binding GO:0033691 8.62 ADIPOQ SELP

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....